GSK — GSK plc

GSK Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Sales: Increased by 5% to over GBP 7.6 billion.
• Core Operating Profit: Grew by 10%.
• Earnings Per Share (EPS): Up by 9%.
• Cash Generation: Strong performance with GBP 1.4 billion generated.
• Dividend: Q1 dividend declared at 17p.
• Gross Margin: Improved by 110 basis points, driven by Specialty Medicines and Shingrix sales.
• R&D Spend: Increased due to accelerated investment in pipeline projects.

2. Strategic Updates and Business Highlights

• Specialty Medicines: Growth of 14%, with Shingrix sales exceeding GBP 1 billion (up 20%).
• Product Launches: Successful launches of Nucala for COPD, Exdensur, and Blenrep, with Nucala capturing 45% market share in COPD.
• Oncology: Jemperli reported significant growth, with promising data from ongoing studies in endometrial and rectal cancers.
• HIV Portfolio: Strong growth of 10%, driven by long-acting treatments like Dovato and Cabenuva, with plans for further pipeline development.
• Business Development: Acquired assets in food allergies and pulmonary hypertension to enhance portfolio.

3. Forward Guidance and Outlook

• Full-Year Guidance: Maintained expectations for profitable growth, with cash flows expected to be weighted towards the second half of the year.
• Pipeline Updates: Anticipated updates on HIV and oncology pipelines in Q2, with a focus on accelerating late-stage assets.
• Market Positioning: Continued emphasis on expanding market share in key therapeutic areas, particularly in COPD and HIV.

4. Bad News, Challenges, or Points of Concern

• General Medicines Decline: Experienced a 6% decrease, attributed to declining sales of older products, with Trelegy growth limited by Medicare redesign.
• Competitive Pressures: Concerns regarding the impact of new competitor products in the HIV space and the potential for formulary restrictions in state programs like ADAP.
• Market Access: Exdensur's uptake is hindered by limited access pending J-code approval, affecting initial market penetration.
• Regulatory Challenges: Ongoing scrutiny and potential hurdles in obtaining necessary approvals for new products.

5. Notable Q&A Insights

• Exdensur Discontinuation Rates: High discontinuation rates (65%) for short-acting biologics primarily due to compliance issues; patients often revert to inhaled medications.
• Pipeline Acceleration: GSK is focused on accelerating late-stage pipeline assets, with regular reviews of clinical execution and resource allocation.
• Bepirovirsen Expectations: Anticipated to be a significant asset in hepatitis B treatment, with discussions around pricing strategies in different markets.
• HIV Market Dynamics: The introduction of a once-weekly oral treatment may impact daily oral regimens but is not expected to significantly affect long-acting injectables.
• Nucala and Exdensur Positioning: Nucala's growth in COPD is strong, and resources are being shifted to support Exdensur's launch, indicating a strategic focus on maximizing both products' potential.

This summary captures the essential financial metrics, strategic initiatives, and challenges faced by GSK in Q1 2026, providing a comprehensive overview for stakeholders.